Updated on 2022/03/31

写真a

 
MORISE Masahiro
 
Organization
Nagoya University Hospital Respiratory Medicine Lecturer of hospital
Title
Lecturer of hospital
Contact information
メールアドレス

Degree 1

  1. 博士(医学) ( 2010.9   名古屋大学 ) 

Research Interests 3

  1. 化学療法に関する支持療法

  2. 悪性胸膜中皮腫

  3. 肺癌

Research History 1

  1. Nagoya University   Nagoya University Hospital   Postgraduate Clinical Training and Career Development Support Center, Deputy Director

    2017.2 - 2019.3

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    - 2010.3

      More details

    Country: Japan

  2. Gifu University   Faculty of Medicine

    - 2000.3

      More details

    Country: Japan

Professional Memberships 6

  1. European Society for Medical Oncology

  2. International Association for The Study Of Lung Cancer

  3. 日本臨床腫瘍学会

  4. 日本呼吸器学会

  5. 日本肺癌学会

  6. 日本内科学会

▼display all

Committee Memberships 3

  1. 日本肺癌学会 ガイドライン検討委員会   薬物療法小委員会 委員  

    2016.12   

  2. 日本肺癌学会 肺癌登録合同委員会   悪性胸膜中皮腫登録事業 委員  

    2016   

  3. 日本肺癌学会 ガイドライン検討委員会   薬物療法および集学的治療小委員会協力委員  

    2014.4 - 2016.12   

 

Papers 58

  1. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE Reviewed International journal

    Hata Akito, Okamoto Isamu, Inui Naoki, Okada Morihito, Morise Masahiro, Akiyoshi Kohei, Takeda Masayuki, Watanabe Yasutaka, Sugawara Shunichi, Shinagawa Naofumi, Kubota Kaoru, Saeki Toshiaki, Tamura Tomohide

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 40 ( 2 ) page: 180 - +   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1200/JCO.21.01315

    Web of Science

    PubMed

  2. Is area under the curve the best parameter for carboplatin induced emetic risk stratification? Reviewed International journal

    Ozone Sachiko, Ichikawa Kazuya, Morise Masahiro, Matsui Akira, Kinoshita Fumie, Matsuzawa Reiko, Koyama Junji, Tanaka Ichidai, Hashimoto Naozumi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 4 ) page: 773 - 785   2021.11

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18999/nagjms.83.4.773

    Web of Science

    PubMed

  3. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With <i>EGFR</i> Mutations. Reviewed International journal

    Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y

    JTO clinical and research reports   Vol. 2 ( 1 ) page: 100107   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtocrr.2020.100107

    PubMed

  4. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC Reviewed International coauthorship International journal

    Herbst Roy S., Giaccone Giuseppe, de Marinis Filippo, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos H., Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Zou Wei, Sandler Alan, Enquist Ida, Komatsubara Kimberly, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, McCleland Mark, Mocci Simonetta, Jassem Jacek, Spigel David R.

    NEW ENGLAND JOURNAL OF MEDICINE   Vol. 383 ( 14 ) page: 1328 - 1339   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1056/NEJMoa1917346

    Web of Science

  5. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Reviewed International journal

    Sugawara Shunichi, Inui Naoki, Kanehara Masashi, Morise Masahiro, Yoshimori Kozo, Kumagai Toru, Fukui Tomoya, Minato Koichi, Iwashima Akira, Takeda Yuichiro, Kubota Kaoru, Saeki Toshiaki, Tamura Tomohide

    CANCER   Vol. 125 ( 22 ) page: 4076 - 4083   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cncr.32429

    Web of Science

  6. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Reviewed International journal

    Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N

    International journal of clinical oncology   Vol. 24 ( 7 ) page: 731 - 770   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-019-01431-z

    Web of Science

    PubMed

  7. 12. Clinical Practice of Lung Cancer in Elderly Patients International journal

    Hasegawa Yoshinori, Morise Masahiro

    Nihon Naika Gakkai Zasshi   Vol. 106 ( 9 ) page: 1986 - 1990   2017.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    DOI: 10.2169/naika.106.1986

    CiNii Research

  8. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE) Reviewed International journal

    Hata Akito, Shiraishi Yoshimasa, Inui Naoki, Okada Morihito, Morise Masahiro, Akiyoshi Kohei, Takeda Masayuki, Watanabe Yasutaka, Sugawara Shunichi, Shinagawa Naofumi, Kubota Kaoru, Saeki Toshiaki, Tamura Tomohide

    ONCOLOGY AND THERAPY     2022.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s40487-022-00188-2

    Web of Science

    PubMed

  9. INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance Reviewed International coauthorship International journal

    Smit Egbert F., Dooms Christophe, Raskin Jo, Nadal Ernest, Tho Lye M., Le Xiuning, Mazieres Julien, Hin How S., Morise Masahire, Zhu Viola W., Tan Daniel, Holmberg Kristina H., Ellers-Lenz Barbara, Adrian Svenja, Brutlach Sabine, Schumacher Karl M., Karachaliou Niki, Wu Yi-Long

    FUTURE ONCOLOGY   Vol. 18 ( 9 ) page: 1039 - 1054   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2217/fon-2021-1406

    Web of Science

  10. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations Reviewed International journal

    Tanaka Ichidai, Morise Masahiro

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   Vol. 23 ( 1 )   2022.1

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/ijms23010245

    Web of Science

    PubMed

  11. Amelanotic Malignant Melanoma with a <i>BRAF V600E</i> Mutation Mimicking Primary Lung Cancer Reviewed International journal

    Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Deoksu Kim, Shimoyama Yoshie, Hashimoto Naozumi

    Internal Medicine   Vol. 61 ( 5 ) page: 703 - 708   2022

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    <p>Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a <i>BRAF V600E</i> mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with <i>BRAF V600E</i> mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression. </p>

    DOI: 10.2169/internalmedicine.6657-20

    Web of Science

    PubMed

    CiNii Research

  12. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer Reviewed International journal

    Yasuda Hiroyuki, Ichihara Eiki, Sakakibara-Konishi Jun, Zenke Yoshitaka, Takeuchi Shinji, Morise Masahiro, Hotta Katsuyuki, Sato Mineyoshi, Matsumoto Shingo, Tanimoto Azusa, Matsuzawa Reiko, Kiura Katuyuki, Takashima Yuta, Yano Seiji, Koyama Junji, Fukushima Takahiro, Hamamoto Junko, Terai Hideki, Ikemura Shinnosuke, Takemura Ryo, Goto Koichi, Soejima Kenzo

    LUNG CANCER   Vol. 162   page: 140 - 146   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lungcan.2021.10.006

    Web of Science

    PubMed

  13. Oxytocin receptor is a promising therapeutic target of malignant mesothelioma Reviewed International journal

    Kodama Yuta, Tanaka Ichidai, Sato Tatsuhiro, Hori Kazumi, Gen Soei, Morise Masahiro, Matsubara Daisuke, Sato Mitsuo, Sekido Yoshitaka, Hashimoto Naozumi

    CANCER SCIENCE   Vol. 112 ( 9 ) page: 3520 - 3532   2021.9

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.15025

    Web of Science

    PubMed

  14. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 Reviewed International journal

    Ito K., Morise M., Wakuda K., Hataji O., Shimokawaji T., Takahashi K., Furuya N., Takeyama Y., Goto Y., Abe T., Kato T., Ozone S., Ikeda S., Kogure Y., Yokoyama T., Kimura M., Yoshioka H., Murotani K., Kondo M., Saka H.

    ESMO OPEN   Vol. 6 ( 3 )   2021.6

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.esmoop.2021.100115

    Web of Science

  15. IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC Reviewed International coauthorship International journal

    Herbst R., De Marinis F., Giaccone G., Vergnenegre A., Barrios C., Morise M., Felip E., Oprean C., Kim Y., Andric Z., Mocci S., Enquist I., Komatsubara K., Mccleland M., Deng Y., Kuriki H., Villalobos M., Phan S., Spigel D., Jassem J.

    JOURNAL OF THORACIC ONCOLOGY   Vol. 16 ( 3 ) page: S224 - S225   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  16. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study Reviewed International coauthorship International journal

    Seto Takashi, Hayashi Hidetoshi, Satouchi Miyako, Goto Yasushi, Niho Seiji, Nogami Naoyuki, Hida Toyoaki, Takahashi Toshiaki, Sakakibara-Konishi Jun, Morise Masahiro, Nagasawa Takashi, Suzuki Mie, Ohkura Masayuki, Fukuhara Kei, Thurm Holger, Peltz Gerson, Nishio Makoto

    CANCER SCIENCE   Vol. 111 ( 10 ) page: 3726 - 3738   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.14576

    Web of Science

  17. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study Reviewed International journal

    Nakano Takashi, Kuribayashi Kozo, Kondo Masashi, Morise Masahiro, Tada Yuji, Hirano Katsuya, Hayashi Morihiko, Tanaka Misa, Hirabayashi Masataka

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ajco.13455

    Web of Science

  18. Clinical burden of immune checkpoint inhibitor-induced pneumonitis Reviewed International journal

    Sakamoto Koji, Fukihara Jun, Morise Masahiro, Hashimoto Naozumi

    RESPIRATORY INVESTIGATION   Vol. 58 ( 5 ) page: 305 - 319   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.resinv.2020.05.008

    Web of Science

  19. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer Reviewed International journal

    Matsui Akira, Morise Masahiro, Tanaka Ichidai, Ozone Sachiko, Matsuzawa Reiko, Koyama Junji, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

    CANCER INVESTIGATION   Vol. 38 ( 7 ) page: 424 - 430   2020.8

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/07357907.2020.1793350

    Web of Science

  20. Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation Reviewed International journal

    Tanaka Ichidai, Morise Masahiro, Miyazawa Ayako, Kodama Yuta, Tamiya Yutaro, Gen Soei, Matsui Akira, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

    CLINICAL LUNG CANCER   Vol. 21 ( 3 ) page: 273 - +   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cllc.2020.01.011

    Web of Science

  21. Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With NoneSmall-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors" Reviewed International journal

    Fukihara Jun, Sakamoto Koji, Koyama Junji, Ito Takayasu, Iwano Shingo, Morise Masahiro, Ogawa Masahiro, Kondoh Yasuhiro, Kimura Tomoki, Hashimoto Naozumi, Hasegawa Yoshinori

    CLINICAL LUNG CANCER   Vol. 21 ( 3 ) page: E205 - E205   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cllc.2019.11.013

    Web of Science

  22. UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer Reviewed International journal

    Goto Daiki, Komeda Kazuki, Uwatoko Natsuki, Nakashima Moeka, Koike Mayu, Kawai Kaho, Kodama Yuta, Miyazawa Ayako, Tanaka Ichidai, Hase Tetsunari, Morise Masahiro, Hasegawa Yoshinori, Kawabe Tsutomu, Sato Mitsuo

    CANCER INVESTIGATION   Vol. 38 ( 4 ) page: 240 - 249   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/07357907.2020.1747483

    Web of Science

  23. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study Reviewed International journal

    Shimokawa Mototsugu, Nosaki Kaname, Seto Takashi, Ohashi Kadoaki, Morise Masahiro, Horinouchi Hidehito, Sakakibara Jun, Murakami Haruyasu, Yano Seiji, Satouchi Miyako, Matsumoto Shingo, Goto Koichi, Yoh Kiyotaka

    TRIALS   Vol. 21 ( 1 )   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s13063-020-4221-7

    Web of Science

  24. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study Reviewed International journal

    Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    BRITISH JOURNAL OF CANCER   Vol. 122 ( 6 ) page: 771 - 777   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41416-020-0736-7

    Web of Science

  25. Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer Reviewed International journal

    Shimizu Takahiro, Okachi Shotaro, Imai Naoyuki, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 1 ) page: 69 - 77   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18999/nagjms.82.1.69

    Web of Science

  26. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Reviewed International journal

    Nakagawa Kazuhiko, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Azuma Koichi, Kim Young Hak, Seto Takashi, Takiguchi Yuichi, Nishio Makoto, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Koyama Ryo, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Hayashi Morihiko, Hasegawa Wakako, Tamura Tomohide

    LUNG CANCER   Vol. 139   page: 195 - 199   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lungcan.2019.11.025

    Web of Science

  27. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study Reviewed International journal

    Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Okuji Takayuki, Ito Masaaki, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Hibi Hideharu, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    JOURNAL FOR IMMUNOTHERAPY OF CANCER   Vol. 8 ( 2 )   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1136/jitc-2020-000779

    Web of Science

  28. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors Reviewed International journal

    Fukihara Jun, Sakamoto Koji, Koyama Junji, Ito Takayasu, Iwano Shingo, Morise Masahiro, Ogawa Masahiro, Kondoh Yasuhiro, Kimura Tomoki, Hashimoto Naozumi, Hasegawa Yoshinori

    CLINICAL LUNG CANCER   Vol. 20 ( 6 ) page: 442 - +   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cllc.2019.07.006

    Web of Science

  29. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations Reviewed International journal

    Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

    LUNG CANCER   Vol. 127   page: 169 - 171   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lungcan.2018.11.018

    Web of Science

    PubMed

  30. eIF2 beta, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer Reviewed International coauthorship International journal

    Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE   Vol. 109 ( 6 ) page: 1843 - 1852   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13602

    Web of Science

    PubMed

  31. Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer

    Okachi Shotaro, Imaizumi Kazuyoshi, Imai Naoyuki, Shimizu Takahiro, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

    EUROPEAN GERIATRIC MEDICINE   Vol. 9 ( 2 ) page: 255-262   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s41999-018-0033-7

    Web of Science

  32. Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study Reviewed International journal

    Shintani Yasushi, Hasegawa Seiki, Takuwa Teruhisa, Aoe Keisuke, Kato Katsuya, Fujimoto Nobukazu, Hida Yasuhiro, Morise Masahiro, Moriya Yasumitsu, Morohoshi Takao, Okumura Meinoshin, Yoshino Ichiro

    JOURNAL OF THORACIC DISEASE   Vol. 10 ( 3 ) page: 1968 - 1971   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21037/jtd.2018.03.53

    Web of Science

    PubMed

  33. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Reviewed International journal

    Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    JOURNAL OF THE ENDOCRINE SOCIETY   Vol. 2 ( 3 ) page: 241 - 251   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1210/js.2017-00432

    Web of Science

    PubMed

  34. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting Reviewed International journal

    Tanaka Ichidai, Kawada Kenji, Morise Masahiro, Hase Tetsunari, Hayashi Hiroaki, Sokai Akihiko, Fukatsu Asuki, Kondo Masashi, Nomura Fumio, Hasegawa Yoshinori

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 81 ( 2 ) page: 339 - 345   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cancer Chemotherapy and Pharmacology  

    DOI: 10.1007/s00280-017-3497-0

    Web of Science

    Scopus

    PubMed

  35. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Reviewed International journal

    Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y

    Internal medicine (Tokyo, Japan)   Vol. 57 ( 23 ) page: 3429 - 3432   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/internalmedicine.0999-18

    Web of Science

    PubMed

  36. Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer Reviewed International coauthorship International journal

    Kakumu Tomohiko, Sato Mitsuo, Goto Daiki, Kato Toshio, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Fukui Takayuki, Yokoi Kohei, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE   Vol. 108 ( 4 ) page: 732 - 743   2017.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13185

    Web of Science

  37. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy. Reviewed

    Omote N, Hashimoto N, Morise M, Sakamoto K, Miyazaki S, Ando A, Nakahara Y, Hasegawa Y.

    Int J Chron Obstruct Pulmon Dis.   Vol. 11 ( 12 ) page: 3541-3547   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  38. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy Reviewed International journal

    Omote Norihito, Hashimoto Naozumi, Morise Masahiro, Sakamoto Koji, Miyazaki Shinichi, Ando Akira, Nakahara Yoshio, Hasegawa Yoshinori

    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE   Vol. 12   page: 3541 - 3547   2017

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.2147/COPD.S149456

    Web of Science

  39. Factors Affecting the Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in Peripheral Lung Cancer. Reviewed

    Okachi S, Imai N, Imaizumi K, Iwano S, Ando M, Hase T, Aso H, Morise M, Wakahara K, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y

    Intern Med   Vol. 55 ( 13 ) page: 1705-12   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  40. The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung Reviewed

    Sekihara K, Hishida T, Ikemura S, Saruwatari K, Morise M, Kuwata T, Fujii S, Kojima M, Ochiai A, Funai K, Aokage K, Yoshida J, Tsuboi M, Ishii G

    J Cancer Res Clin Oncol   Vol. 142 ( 5 ) page: 905-912   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  41. Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? Reviewed

    Kato T, Morise M (equal first author), Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y

    Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?   Vol. 142 ( 7 ) page: 1629-40   2016

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  42. Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung Reviewed

    Udagawa H, Ishii G, Morise M, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A, Ohe Y

    J Cancer Res Clin Oncol   Vol. 141 ( 8 ) page: 1417-25.   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  43. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy

    Koriyama H, Ishii G, Yoh K, Neri S, Morise M, Umemura S, Matsumoto S, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A

    J Cancer Res Clin Oncol   Vol. 141 ( 7 ) page: 1163-70   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  44. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung Reviewed

    Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K, Ishii G

    Journal of cancer research and clinical oncology     page: 2015 May 12. [Epub ahead of print]   2015

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: May 12. [Epub ahead of print]

  45. Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma Reviewed

    Aramaki N, Ishii G, Yamada E, Morise M, Aokage K, Kojima M, Hishida T, Yoshida J, Ikeda N, Tsuboi M, Ochiai A

      Vol. 142 ( 1 ) page: 37-46   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  46. Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System Reviewed

    Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y

    Mol Clin Oncol   Vol. 2 ( 6 ) page: 991-996   2014

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  47. Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer Reviewed

    Morise M, Niho S, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y

    Jpn J Clin Oncol   Vol. 44 ( 9 ) page: 846-51   2014

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  48. Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis Reviewed

      Vol. 9 ( 9 ) page: 1324-31   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  49. 最新がん薬物療法学 小細胞肺癌 Invited

    森瀬昌宏, 後藤功一

    日本臨床 増刊号   Vol. 72 ( 2 ) page: 346-349   2014

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  50. 環境因子と呼吸器悪性腫瘍 Invited

    森瀬昌宏, 長谷川好規

    呼吸と循環   Vol. 62 ( 10 ) page: 963-968   2014

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  51. 講座 肺癌化学療法の最前線 小細胞肺癌に対する化学療法 Invited

    森瀬昌宏, 後藤功一

    呼吸   Vol. 32 ( 7 ) page: 631-637   2013

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  52. 特集 オンコロジーエマージェンシーと支持療法の進歩 抗がん剤による過敏反応,インフュージョンリアクション Invited

    森瀬昌宏, 後藤功一

    呼吸器内科   Vol. 23   page: 261-267   2013

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  53. Nongenomic effects of fluticasone propionate and budesonide on human airway anion secretion Reviewed

    Mizutani T, Morise M, Ito Y, Hibino Y, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y

    Am J Respir Cell Mol Biol   Vol. 47 ( 5 ) page: 645-51   2012

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  54. Capsaicinoids regulate airway anion transporters through Rho kinase- and cyclic AMP-dependent mechanisms Reviewed

    Hibino Y, Morise M, Ito Y, Mizutani T, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y

    Am J Respir Cell Mol Biol   Vol. 45 ( 4 ) page: 684-91   2011

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  55. Heterologous regulation of anion transporters by menthol in human airway epithelial cells Reviewed

    Morise M, Ito Y, Matsuno T, Hibino Y, Mizutani T, Ito S, Hashimoto N, Kondo M, Imaizumi K, Hasegawa Y

    Eur J Pharmacol   Vol. 10 ( 635 ) page: 204-211   2010

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  56. Dual pathway activated by tert-butyl hydroperoxide in human airway anion secretion

    Matsuno T, Ito Y, Ohashi T, Morise M, Takeda N, Shimokata K, Imaizumi K, Kume H, Hasegawa Y

    J Pharmacol Exp Ther   Vol. 327 ( 2 ) page: 453-64   2008

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  57. 肺病変を伴ったmulticentiric Castleman’s diseaseの一例 Reviewed

    森瀬昌宏, 下元博史, 本多 豊大, 森 良雄

    日本呼吸器学会誌   Vol. 41   page: 59-65   2003

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  58. 胸壁原発悪性線維性組織球腫の1例 Reviewed

    下元博史, 森瀬昌宏, 佐藤榮作, 山内晶司

    日本胸部臨床   Vol. 62 ( 6 ) page: 561 -566   2003

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

Books 8

  1. 肺癌診療ガイドライン 2018年版.

    日本肺癌学会ガイドライン委員会 ガイドライン委員( Role: Joint editor)

    金原出版  2018 

     More details

    Language:Japanese Book type:Scholarly book

  2. 肺癌診療ガイドライン 2017年版. IV期非小細胞肺癌薬物療法.

    日本肺癌学会ガイドライン委員会( Role: Joint editor)

    金原出版  2017 

     More details

    Language:Japanese Book type:Scholarly book

  3. EBMの手法による肺癌診療ガイドライン 2016年版

    日本肺癌学会 ガイドライン委員会( Role: Contributor)

    金原出版  2016 

     More details

    Language:Japanese

  4. 胸部X線読影セミナー 第7回 日本医事新報

    森瀬昌宏, 大松広伸, 大江裕一郎( Role: Joint author)

    日本医事新報社  2013 

     More details

    Language:Japanese

  5. レジメン別看護速習覚え書き 肺癌

    森瀬昌宏, 大江裕一郎( Role: Joint author)

    メディカ出版  2012 

     More details

    Language:Japanese

  6. 小細胞肺癌に用いる抗がん剤の副作用;予測と対策

    佐藤光夫, 森瀬昌宏, 長谷川好規( Role: Joint author)

    へるす出版  2012 

     More details

    Language:Japanese

  7. 症例から学ぶメディカルオンコロジー 局所進行非小細胞肺癌症例

    森瀬昌宏、長谷川好規( Role: Sole author)

    医薬ジャーナル社  2011.10 

     More details

    Language:Japanese

  8. コリンズスターン 胸部画像診断エッセンシャル 9章 胸膜、胸壁、横隔膜 訳

    森瀬昌宏, 下方智也( Role: Joint author)

    西村書店  2011.4 

     More details

    Language:Japanese

▼display all

Presentations 55

  1. 非小細胞肺癌における免疫チェックポイント阻害剤と細胞障害性抗癌薬との併用 Invited

    森瀬昌宏

    第60回日本呼吸器学会学術講演会  2020.9  一般社団法人日本呼吸器学会

     More details

    Event date: 2020.9

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  2. 肺癌に対する免疫療法の近未来的展望 放射線治療との併用 Invited

    森瀬昌宏

    第59回日本呼吸器学会学術講演会 

     More details

    Event date: 2019.4

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Country:Japan  

  3. 小細胞肺癌をはじめとする肺神経内分泌腫瘍に対する治療~肺癌診療ガイドラインにおける治療推奨を踏まえて Invited

    森瀬昌宏

    第61回日本肺癌学会学術講演会  2020.11.25  特定非営利法人 日本肺癌学会

     More details

    Event date: 2020.11

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  4. Does the histological differentiation of NSCLC affect the efficacy of immune checkpoint inhibitors?

    Masahiro Morise, Sho Hori, Reiko Matsuzawa, Junji Koyama, Sachiko Ozone, Ichidai Tanaka, Tetsunari Hase, Koji Sakamoto, Shuichi Asano, Yasuhiro Kondoh, Naozumi Hashimoto

    2020.11.26 

     More details

    Event date: 2020.10

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  5. 外来肺癌治療の現状と課題 Invited

    森瀬昌宏

    第28回日本呼吸ケア・リハビリテーション学会学術集会 

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Country:Japan  

  6. The indication of primary prevention for febrile neutropenia (FN) in elderly NSCLC patients treated with docetaxel. International conference

    Morise M, Kondo M, Hasegawa Y.

    2016 the Japanese Society of Medical Oncology Annual Meeting 

     More details

    Event date: 2016.7

    Language:English   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  7. The efficacy and safety of re-challenge platinum plus pemtrexed combination therapy for recurrent malignant pleural mesothelioma International conference

    Mariko Morishita, Masahiro Morise, Tetsunari Hase, Mitsuo Sato, Masashi Kondoh, Yoshinori Hasegawa.

    16th World Conference on Lung Cancer 

     More details

    Event date: 2015.9

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  8. Clinicopathological analysis of SRE in patients with SCLC and NSCLC International conference

    Morise M, Kondo M, Hasegawa Y

    Japan Society of Medical Oncology Annual meeting 2015 

     More details

    Event date: 2015.7

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  9. The prophylactic antiemetic treatment failure in patients with lung cancer treated with CBDCA based-chemotherapy International conference

    Ichikawa K, Morise M, Miyazaki M, Hase T, Kondo M, Hasegawa Y, Yamada K

    Japan Society of Medical Oncology Annual meeting 2015 

     More details

    Event date: 2015.7

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

  10. Can we predict serious adverse events (SAEs) and clarify unfit population for platinum-based chemotherapy in elderly patients (over 70 years of age) with advanced Non-small cell lung cancer (NSCLC)? (CJLSG 1203 trial) International conference

    Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindo J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Kondo M, Saito H, Hasegawa Y.

    European Society of Medical Oncology Annual meeting 2014 

     More details

    Event date: 2014.9

    Language:English   Presentation type:Poster presentation  

    Country:Spain  

  11. Clinicopathological analysis of long-term (more than 2 years) progression-free survivors treated with epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive non-small cell lung cancer. International conference

    Masahiro Morise, Koichi Goto, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Kanji Nagai, Yuichiro Ohe.

    15th World Conference on Lung Cancer 

     More details

    Event date: 2013.10

    Language:English   Presentation type:Poster presentation  

    Country:Australia  

  12. Final results of EGFR mutation reanalysis and KRAS mutation screening by Scorpion ARMS method: Phase II Study of Erlotinib for EGFR wild type Non-small cell Lung Cancer Patients. Central Japan Lung Study Group (CJLSG) 0903 trial. International conference

    Eiichi Maruyama, Masahiro Morise, Tetsunari Hase, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Kenji Ogawa, Takuya Ikeda, Yasuhiro Nozaki, Masahiko Ando, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

    15th World Conference on Lung Cancer 

     More details

    Event date: 2013.10

    Language:English   Presentation type:Oral presentation (general)  

    Country:Australia  

  13. Phase II Study of Erlotinib for previously treated Non-small-cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation: Central Japan Lung Study Group (CJLSG) 0903 trial International conference

    Masahiro Morise, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Tetsunari Hase, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

     More details

    Event date: 2012.9

    Language:English   Presentation type:Poster presentation  

    Country:Austria  

  14. 高齢者非小細胞肺癌に対するプラチナ製剤併用療法に関する多施設共同後向き観察研究 (Central Japan Lung Study Group 1203試験)

    田中健太郎、森瀬昌宏、安藤昌彦、加藤俊夫、小島英嗣、小笠原智彦、鈴木隆二郎、進藤丈、松本政実、杉野安輝、野﨑裕広、小川雅弘、長谷哲成、近藤征史、斉藤博、長谷川好規

    第55回日本呼吸器学会学術講演会 

     More details

    Event date: 2015.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  15. 再発小細胞肺癌に対しアムルビシン単剤療法を施行した患者の予後因子の検討

    森瀬昌宏, 麻生裕紀, 長谷哲成, 若原恵子, 伊藤理, 橋本直純, 佐藤光夫, 近藤征史, 長谷川好規

    第52回日本癌治療学会総会 

     More details

    Event date: 2014.8

    Language:Japanese   Presentation type:Poster presentation  

    Venue:横浜   Country:Japan  

  16. EGFR-TKIにより2年以上の長期無増悪生存が得られるEGFR遺伝子変異陽性非小細胞肺癌の臨床病理学的検討

    森瀬昌宏、後藤功一、梅村茂樹、松本慎吾、葉清隆、仁保誠治、大松広伸、永井完治、大江裕一郎

    第54回日本肺癌学会総会 

     More details

    Event date: 2013.11

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京   Country:Japan  

  17. Capsaicinoids regulate airway anion transporters through Rho kinase- and cAMP-dependent mechanisms

     More details

    Event date: 2013.5

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  18. 再発小細胞肺癌に対する60mg/m2・3週投与1週休薬法によるイリノテカン単剤療法の検討 International conference

    森瀬昌宏、仁保誠治、梅村茂樹、松本慎吾、葉清隆、後藤功一、大松広伸、大江裕一郎

    第53回日本肺癌学会総会 

     More details

    Event date: 2012.10

    Language:English   Presentation type:Oral presentation (general)  

    Venue:岡山   Country:Japan  

  19. Prognostic Factors in Recurrent Small Cell Lung Carcinoma International conference

    Masahiro Morise, Takefumi Mizutani, Tomoyo Oguri, Naoyuki Imai, Tetsunari Hase, Yuichiro Shindo, Yoshihiro Inukai, Satoru Ito, Naozumi Hashimoto, Mitsuo Sato, Masashi Kondo, Yoshinori Hasegawa.

    Japan Society of Medical Oncology Annual meeting 

     More details

    Event date: 2012.7

    Language:English   Presentation type:Poster presentation  

    Country:Japan  

  20. Prospective Analysis of Efficacy and Safety of Individualized Administration of Midazolam for Sedation During Bronchoscopy International conference

    Imaizumi K, Hashimoto I, Shindo Y, Imai N, Ogawa T, Morise M, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y

    CHEST 2011 

     More details

    Event date: 2011.10

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  21. ヒト気道上皮のイオン輸送体に対するmentholの細胞骨格を介した制御 International conference

    森瀬昌宏、伊藤康、日比野佳孝、伊藤理、橋本直純、近藤征史、今泉和良、長谷川好規

    アレルギー学会総会秋季大会 

     More details

    Event date: 2010.10

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京   Country:Japan  

  22. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC International coauthorship International conference

    Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z. G., Geater S., Ozguroglu M., Mocci S., McCleland M., Enquist I., Komatsubara K. M., Deng Y., Kuriki H., Wen X., Jassem J., Herbst R. S.

    ANNALS OF ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  23. Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC International coauthorship International conference

    Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

    ANNALS OF ONCOLOGY  2020.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  24. Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference

    Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  25. A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan) International conference

    Daga Haruko, Umemura Shigeki, Ohe Yuichiro, Shiota Tetsuhiro, Fujita Masaki, Furuya Naoki, Tsuda Takeshi, Morise Masahiro, Matsumoto Shingo, Goto Koichi

    ANNALS OF ONCOLOGY  2017.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  26. Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer International conference

    Oi H., Yamano Y., Yokoyama T., Matsuda T., Morise M., Kataoka K., Kimura T., Kondoh Y.

    ANNALS OF ONCOLOGY  2019.11 

     More details

    Language:Japanese   Presentation type:Poster presentation  

  27. UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer International conference

    Goto D., Kizuki M., Uwatoko N., Kawai K., Koike M., Nakashima M., Miyazawa A., Tanaka I., Hase T., Morise M., Hasegawa Y., Minna J., Sato M.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  28. The Subunit eIF2 ss of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer International conference

    Sato Mitsuo, Tanaka Ichidai, Goto Daiki, Kato Toshio, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE  2018.12 

     More details

    Presentation type:Poster presentation  

  29. Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A International coauthorship International conference

    Mazieres J., Paik P., Felip E., Veillon R., Sakai H., Cortot A., Viteri S., Garassino M., Van Meerbeeck J., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

    JOURNAL OF THORACIC ONCOLOGY  2021.1 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  30. Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data International coauthorship International conference

    Sakai H., Felip E., Cortot A. B., Veillon R., Griesinger F., Patel J., Horn L., Mazieres J., De Castro Carpeno J., Morise M., Sakamoto T., Bruns R., Scheele J., Straub J., Paik P.

    ANNALS OF ONCOLOGY  2018.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  31. Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A International coauthorship International conference

    Mazieres J., Paik P. K., Felip E., Veillon R., Sakai H., Cortot A. B., Viteri S., Garassino M. C., Van Meerbeeck J. P., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

    ANNALS OF ONCOLOGY  2020.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  32. Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study International coauthorship International conference

    Sakai Hiroshi, Veillon Remi, Cortot Alexis B., Felip Enriqueta, Mazieres Julien, Morise Masahiro, Sakamoto Tomohiro, Tokito Takaaki, Atagi Shinji, Kato Terufumi, Kumagai Toru, Tanaka Hiroshi, Bruns Rolf, Straub Josef, Scheele Juergen, Le Xiuning, Paik Paul K.

    ANNALS OF ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  33. Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study International conference

    Park K., Felip E., Veillon R., Cortot A., Mazieres J., Sakai H., Reinmuth N., Viteri S., Chen Y-M., Han J-Y., Jang T-W., Morise M., Sakamoto T., Tokito T., Cho B. C., Bruns R., Scheele J., Straub J., Le X., Paik P. K.

    ANNALS OF ONCOLOGY  2019.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  34. Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping International coauthorship International conference

    Yang J. C-H., Le X., Cho B. C., Han J-Y., Morise M., Chen Y-M., Kang J-H., Kato T., Takeoka H., Chikamori K., Sakai H., Park K., Wu Y-L., Schumacher K., Bruns R., Straub J., Paik P.

    ANNALS OF ONCOLOGY  2020.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  35. Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC International coauthorship International conference

    Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M., Stanton T., Morise M., Lee J. -S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P.

    JOURNAL OF THORACIC ONCOLOGY  2021.1 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  36. Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy International conference

    Hase T., Miyazaki M., Ichikawa K., Yogo N., Ozawa N., Ando M., Morise M., Sato M., Kondo M., Yamada K., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2018.10 

     More details

    Language:English   Presentation type:Poster presentation  

  37. Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC International conference

    Matsuzawa R., Morise M., Tanaka I., Koyama J., Kimura T., Kondoh Y., Hase T., Sakamoto K., Hashimoto N., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Poster presentation  

  38. Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer International conference

    Fukihara J., Sakamoto K., Iwano S., Morise M., Hashimoto N., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2018 

     More details

    Language:English   Presentation type:Poster presentation  

  39. PREDICT1: An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201). International conference

    Hase Tetsunari, Yanagisawa Kiyoshi, Fukatsu Asuki, Kimura Tomoki, Kojima Eiji, Abe Takashi, Imaizumi Kazuyoshi, Horio Yoshitsugu, Oguri Tetsuya, Yamamoto Masashi, Ogasawara Tomohiko, Sugino Yasuteru, Morise Masahiro, Nakatochi Masahiro, Ando Masahiko, Kondo Masashi, Saka Hideo, Saito Hiroshi, Hasegawa Yoshinori, Takahashi Takashi

    JOURNAL OF CLINICAL ONCOLOGY  2020.5.20 

     More details

    Language:English   Presentation type:Poster presentation  

  40. Phase II study of tepotinib in NSCLC patients with METex14 mutations. International coauthorship International conference

    Paik Paul K., Veillon Remi, Cortot Alexis B., Felip Enriqueta, Sakai Hiroshi, Mazieres Julien, Griesinger Frank, Horn Leora, Senellart Helene, Van Meerbeeck Jan P., de Castro Carpeno Javier, Patel Jyoti D., Garassino Marina Chiara, Morise Masahiro, Reinmuth Niels, Viteri Santiago, Tokito Takaaki, Sakamoto Tomohiro, Scheele Juergen, Le Xiuning

    JOURNAL OF CLINICAL ONCOLOGY  2019.5.20 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  41. Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). International conference

    Udagawa Hibiki, Ikeda Takaya, Umemura Shigeki, Daga Haruko, Toyozawa Ryo, Harada Daijiro, Sakakibara-Konishi Jun, Morise Masahiro, Yamamoto Noboru, Takahashi Toshiaki, Kato Terufumi, Shingyoji Masato, Ushio Ryota, Hara Satoshi, Takata Saori, Nomura Shogo, Matsumoto Shingo, Niho Seiji, Sato Akihiro, Goto Koichi

    JOURNAL OF CLINICAL ONCOLOGY  2020.5.20 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  42. Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study International conference

    Shimokawa M., Nosaki K., Seto T., Ohashi K., Morise M., Fujiwara Y., Sakakibara J., Murakami H., Yano S., Satouchi M., Matsumoto S., Goto K., Yoh K.

    ANNALS OF ONCOLOGY  2019.4 

     More details

    Language:English   Presentation type:Poster presentation  

  43. IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC International coauthorship International conference

    Herbst Roy, De Marinis Filippo, Giaccone Giuseppe, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos, Morise Masahiro, Font Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Mocci Simonetta, McCleland Mark, Enquist Ida, Komatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Spigel David

    JOURNAL FOR IMMUNOTHERAPY OF CANCER  2020.4 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  44. Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC International coauthorship International conference

    Reinmuth Niels, Spigel David, De Marinis Filippo, Giaccone Giuseppe, Verynenegre Alain, Barrios Carlos Henrique, Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozgueroglur Mustafa, Mocci Simonetta, Mccleland Mark, Enquist Ida, Kotnatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Herbst Roy S.

    ONCOLOGY RESEARCH AND TREATMENT  2020.2 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  45. Impact Of Mild To Moderate COPD On Prognosis And Feasibility For Chemotherapy In Patients With Lung Cancer

    Omote N., Hashimoto N., Morise M., Miyazaki S., Ando A., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2017 

     More details

    Presentation type:Oral presentation (general)  

  46. Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT International conference

    Tamiya Y., Morise M., Matsuzawa R., Tanaka I., Okada T., Iwano S., Hase T., Hashimoto N., Sato M., Itoh Y., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

  47. Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status International conference

    Koyama Junji, Kimura Tomoki, Oi Hajime, Yamano Yasuhiko, Yokoyama Toshiki, Matsuda Toshiaki, Kataoka Kensuke, Matsuzawa Reiko, Fukihara Jun, Sakamoto Koji, Morise Masahiro, Hashimoto Naozumi, Kondoh Yasuhiro, Hasegawa Yoshinori

    ANNALS OF ONCOLOGY  2019.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

  48. Identification of Proteosomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen International conference

    Sato M., Kakumu T., Goto D., Kato T., Yogo N., Hase T., Morise M., Fukui T., Yokoi K., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2017.11 

     More details

    Language:English   Presentation type:Poster presentation  

  49. Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC). International conference

    Seto Takashi, Nishio Makoto, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Kim Young Hak, Azuma Koichi, Takiguchi Yuichi, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Nakagawa Kazuhiko, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Tamura Tomohide

    JOURNAL OF CLINICAL ONCOLOGY  2019.5.20 

     More details

    Language:English   Presentation type:Poster presentation  

  50. eIF2 beta, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer International conference

    Goto D., Tanaka I., Sato M., Kato T., Miyazawa A., Hase T., Morise M., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2018.10 

     More details

    Language:English   Presentation type:Poster presentation  

  51. Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung International conference

    Morise Masahiro, Hishida Tomoyuki, Takahashi Akiko, Yoshida Junji, Ohe Yuichiro, Nagai Kanji, Ishii Genichiro

    JOURNAL OF THORACIC ONCOLOGY  2017.1 

     More details

    Language:English   Presentation type:Poster presentation  

  52. Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study International coauthorship International conference

    Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D. R., Jassem J.

    ANNALS OF ONCOLOGY  2019.12 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  53. Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 International coauthorship International conference

    Herbst R. S., De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D., Jassem J.

    SWISS MEDICAL WEEKLY  2020.11.18 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  54. Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference

    Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  55. Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC International coauthorship International conference

    Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

    ANNALS OF ONCOLOGY  2020.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

▼display all

Research Project for Joint Research, Competitive Funding, etc. 9

  1. Phase II study of docetaxel plus ramucirumab after treatment of platinum based chemotherapy combined with immune check point inhibitors in patients with non-small cell lung cancer

    2019.11

  2. 進行肺癌の血漿遊離DNAを利用したマルチ遺伝子解析法に基づく個別化医療の確立を目指した研究(AMED)

    2019.4 - 2022.3

    革新的がん医療実用化研究事業  

      More details

    Grant type:Competitive

  3. 希少遺伝子変異を有する小細胞肺癌に対する新規治療法の確立に関する研究 (AMED)

    2019.4 - 2020.3

    革新的がん医療実用化研究事業 

      More details

    Grant type:Competitive

  4. ROS1融合遺伝子陽性の進行固形がんに対する治療開発を目指した研究 (AMED)

    2018.10 - 2021.3

    革新的がん医療実用化研究事業 

      More details

    Grant type:Competitive

  5. RET肺がんに対するアレクチニブの医師主導治験と耐性機構解析 (AMED)

    2018.4 - 2020.3

    革新的がん医療実用化研究事業 

      More details

    Grant type:Competitive

  6. 次世代シークエンサーによる網羅的がん関連遺伝子パネル解析を用いたHER2遺伝子変異陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

    2018 - 2019

    革新的がん医療実用化研究事業  

    岡本勇

      More details

    Grant type:Competitive

  7. 悪性胸膜中皮腫に対する血管新生阻害剤の効果予測モデル構築に基づく新治療法確立に関する研究 (AMED)

    2017.9 - 2018.3

    革新的がん医療実用化研究事業 

    長谷川好規

      More details

    Grant type:Competitive

  8. 遺伝子スクリーニング基盤(LC-SCRUM-Japan)を利用した、MET遺伝子異常陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

    2017.4 - 2020.3

    革新的がん医療実用化研究事業  

      More details

    Grant type:Competitive

  9. Efficacy and safety of oral granisetron and dexamethasone for crizotinib-induced nausea and vomiting in patient with non-small cell lung cancer (NSCLC)

    2015.1

    Cooperative Research within Japan 

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 4

  1. 高齢進行肺癌患者における、VES-13ならびにMMSEの有用性に関する検討

    2013.4 - 2016.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Coinvestigator(s) 

  2. 呼吸器悪性腫瘍における血管新生阻害治療の低侵襲な効果予測法を確立をめざす研究

    Grant number:19K07910  2019.4 - 2023.3

    森瀬 昌宏

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    呼吸器悪性腫瘍(肺癌・悪性胸膜中皮腫・胸腺腫瘍)は、いずれも予後が不良の疾患です。これらの腫瘍の増殖、転移には腫瘍内の血管新生が大きく関与しているため、血管新生阻害治療が重要な治療法の一つとして注目されています。しかし、血管新生阻害治療が有効な患者さんを事前に判定する効果予測法は確立されていません。本研究は、血管新生の過程に重要な蛋白であるVEGF-Aに着目して、体に負担の少ない方法での血管新生阻害剤の効果を予測する方法を確立することを目指します。
    悪性胸膜中皮腫の症例に関して、患者背景、標準治療であるシスプラチン・ペメトレキセド、ニボルマブの各治療効果を含む臨床データを集積した。胸膜剥皮、胸膜肺全摘術を含む外科治療との集学的治療症例に関しても各治療効果を含む臨床データの集積を完了した。悪性胸膜中皮腫においては、腫瘍volumeと腫瘍から産生されるVEGF-A量の相関が存在する可能性を想定しており、volume softwareを用いた腫瘍量測定の実施を完了した。今後、VEGF-A発現との相関について解析を実施していく予定である。肺癌症例に関しては、血管新生促進型VEGF-A165a/抑制型VEGF-A165b産生能のheterogeneity評価として進行肺癌症例におけるVEGF-A165a/VEGF-A165bバランスを血漿Total VEGF-A, VEGF-A165bを同時に評価する方法で解析を実施した。解析の結果、個々の症例ごとにVEGF-A165a/VEGF-A165bバランスにはheterogeneityが存在することが確認された。現在、進行肺癌において血管新生阻害剤は、初回治療、二次治療両者で実用化されている。すなわち初回治療において抗VEGF-A抗体のベバシズマブは、従来から実用化されていたEGFRチロシンキナーゼ阻害剤、プラチナ併用化学療法との併用に加えて、免疫療法と血管新生阻害剤の併用療法の有効性が注目されており、今後、これらの治療をうける患者の治療前血漿にてVEGF-A165a/VEGF-A165bバランスの評価を行っていく予定である。また既治療例においてもVEGFR-2受容体阻害剤が殺細胞性抗がん剤であるドセタキセルとの併用で生存延長効果を示しており、これらの薬剤に関する効果予測手法についても検討を継続していく計画である。
    胸膜中皮腫の臨床コホート集積を完了した。肺癌症例ではVEGF-A165a/VEGF-A165bバランスにはheterogeneityが存在することから血管新生阻害剤治療群と非治療群を集積し、効果予測因子、予後予測因子の判別解析で血管新生阻害治療の効果予測法の確立について検討をすすめていく方針である。
    肺癌症例において血管新生阻害剤治療群と非治療群を集積し、効果予測因子、予後予測因子の判別解析で血管新生阻害治療の効果予測法の確立について検討をすすめていく方針である。

  3. Fundamental research for treatment optimization in elderly patients with mesothelioma

    Grant number:15K08905  2015.4 - 2018.3

    MASAHIRO MORISE

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    Chemotherapy induced nausea and vomitting (CINV) can be associated with discontinuation of cisplatin plus pemetrexed/carboplatin plus pemetrexed, which are standard regimen for advanced malignant mesothelioma. Based on our research, pemetrexed regimen showed higer indcidence of CINV compared to non-pemetrexed 3rd generation anticancer drugs.

  4. 悪性中皮腫におけるオキシトシン受容体を標的とした新規治療法の開発

    Grant number:20H03689  2020.4 - 2023.3

    田中 一大

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    悪性中皮腫は希少な腫瘍であるが極めて予後不良であり、新規治療法の開発が切望されている。研究代表者はこれまでの解析で、約40%の悪性中皮腫において著しく高発現している受容体に着眼し、独立した予後予測因子であることを発見した。さらにin vitro の解析で、同遺伝子をノックダウンすると、中皮腫細胞株の増殖が有意に抑制されることを見出した。これらの結果を基軸に、本研究では1)悪性中皮腫における同受容体下流の細胞内シグナル経路の解明、2)同受容体阻害剤の抗腫瘍効果の検証、3)さらに悪性中皮腫の組織検体を用いて免疫染色を施行し、同受容体を標的とした治療対象を選出するプロトコルの最適化を行う。

 

Social Contribution 1

  1. 医療従事者に知ってほしい肺がん医療 講演「医療従事者に知ってほしい肺がんの最新治療」

    2015.8